Following a CHF 2.4 million seed round, Aseptuva progressed to preclinical validation
Last year Swiss-UK Medtech startup Aseptuva raised CHF 2.4 million from prominent healthcare entrepreneurs and investors, enabling the company to move from early prototyping to preclinical validation in Europe. The funding supported interviews with clinical staff, iterative product development with partners such as Philips Innovation Services and Fraunhofer FEP, and successful preclinical efficacy testing in the UK. Aseptuva’s Far‑UVC disinfection technology targets bloodstream infections associated with intravenous catheters, aiming to reduce infection risk and reliance on antibiotics.
Last year Swiss-UK Medtech startup Aseptuva raised CHF 2.4 million from prominent healthcare entrepreneurs and investors, enabling the company to move from early prototyping to preclinical validation in Europe. The funding supported interviews with clinical staff, iterative product development with partners such as Philips Innovation Services and Fraunhofer FEP, and successful preclinical efficacy testing in the UK. Aseptuva’s Far‑UVC disinfection technology targets bloodstream infections associated with intravenous catheters, aiming to reduce infection risk and reliance on antibiotics.
The article highlights Swiss investment in medtech innovation, but it does not mention AI involvement.
Original source record. Open the original record to verify the underlying announcement.